Skip to main content

Gout — Deal Benchmarks & Valuation

Median Upfront
$552M
Range: $303M - $790M
Total Deal Value
$2.6B
Range: $1.7B - $3.5B
Royalty Rate
13.7% - 25%
Tiered up to 29%
Dev Milestones
$371M
Range: $251M - $493M
Model Your Deal

Market Analysis

Gout is one of the most actively transacted indications in metabolic licensing. Phase 2 deals for gout carry a median total deal value of $2.6B, with upfront payments ranging from $303M to $790M. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones.

Milestone structures for gout deals allocate $371M to development milestones, $454M to regulatory milestones, and $1.2B to commercial milestones. Royalty rates range from 13.7% to 25% at the base tier, with tiered escalation reaching 17.7%-29% on peak sales.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for gout licensing?
Phase 2 gout licensing deals average $552M in upfront payments with $2.6B total deal value. The 21/79 upfront/milestone split reflects the risk profile at this clinical stage.
What royalty rates are standard for gout deals?
Base royalty rates for gout transactions range from 13.7% to 25%, with tiered escalations reaching 17.7%-29% on peak sales. Rates are influenced by mechanism differentiation, competitive positioning, and territorial scope.
How are gout deal milestones structured?
Gout deals allocate approximately 79% of total deal value to milestones. Development milestones ($371M) make up the largest share, followed by commercial milestones ($1.2B) and regulatory milestones ($454M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Obesity Deals

View

Type 2 Diabetes Deals

View

NASH / MASH Deals

View

Metabolic Deal Overview

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included